YM155 (Sepantronium Bromide)

Catalog No.S1130

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfLOW04OiCq NI\3bFJFVVOR MULJR|UxRTBwMEC5JOKyKDBwMECwPUDPxE1? MXmyOVY2QTd|MR?=
M-07e MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP1eJM4OiCq M3GzUGROW09? M{fhRmlEPTB;MD6wOFAhyrFiMD6wNVMh|ryP M3\hZ|I2PjV7N{Ox
THP-1 NY\ze|hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEmzdng4OiCq M4q4WmROW09? MnHZTWM2OD1yLkC1NUDDuSByLkCxN{DPxE1? NUPBXIUxOjV4NUm3N|E>
CMK NXXtRohIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT2OlRyPzJiaB?= NYTWVY5qTE2VTx?= M4[2RWlEPTB;MD6wOVMhyrFiMD6wNFkh|ryP NVvUO2RPOjV4NUm3N|E>
MV4-11 M2fvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nlWFczKGh? NIC4VIhFVVOR NXTFUoR4UUN3ME2wMlA2PSEEsTCwMlAzQCEQvF2= MmDJNlU3PTl5M{G=
AML-193 M3vne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYK3NkBp NHTPR4dFVVOR MXPJR|UxRTBwNE[yJOKyKDBwME[wJO69VQ>? MUGyOVY2QTd|MR?=
HL-60 NU\MfWRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPEO|IhcA>? NFnLT4lFVVOR MoLjTWM2OD1yLkCwNUDDuSByLkCwNFIh|ryP NUTYcYZIOjV4NUm3N|E>
ML-2 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ORmtzPzJiaB?= MnvSSG1UVw>? M3Hn[2lEPTB;MD6wNFkhyrFiMD6wNFIh|ryP M4POOFI2PjV7N{Ox
OCI/AML3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3DO|IhcA>? MlnOSG1UVw>? MX3JR|UxRTBwMEGxJOKyKDBwMECyJO69VQ>? MWqyOVY2QTd|MR?=
HEL NED1cWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTqO|IhcA>? NYr0bld6TE2VTx?= NGHNVYdKSzVyPUCuOVU6KMLzIECuNFM5KM7:TR?= NETLeXMzPTZ3OUezNS=>
ME-1 NEXLXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD5OnM6PzJiaB?= MU\EUXNQ NHTMSmxKSzVyPUCuOlg1KMLzIECuNVc6KM7:TR?= MlL5NlU3PTl5M{G=
THP-1 MVTBdI9xfG:|aYOgRZN{[Xl? M2nMU|HDqM7:TR?= NVfnR4hVPzJiaB?= Mn:zSG1UVw>? NWXK[oZicW6mdXPld{BieG:ydH;zbZM> NXTCZml7OjV4NUm3N|E>
M-07e MVnGeY5kfGmxbjDBd5NigQ>? MkS1NQKBmzIEoN88US=> NIHCR4M4OiCq M1\KWGROW09? MYPpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw Moe4NlU3PTl5M{G=
THP-1 M13vb2Z2dmO2aX;uJGF{e2G7 MoW4NQKBmzIEoN88US=> M1:1PVczKGh? Ml3hSG1UVw>? MVnpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw Mo\rNlU3PTl5M{G=
CMK NWTaV5ZMTnWwY4Tpc44hSXO|YYm= NHXacpYx6oDVMdMg{txO NXTMW5NIPzJiaB?= NXzjVI15TE2VTx?= M3:z[Ylv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= M4S1[lI2PjV7N{Ox
AML-193 NGfBXoJHfW6ldHnvckBCe3OjeR?= M{Xhb|DjiJNzwrFOwG0> NWH6O4Z4PzJiaB?= NGTSNIhFVVOR M17NNolv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= MnPBNlU3PTl5M{G=
Kasumi-1 NYjjcZJMTnWwY4Tpc44hSXO|YYm= MYiw5qCUOcLizszN M2TNdlczKGh? M{DYZWROW09? MoflbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= MYmyOVY2QTd|MR?=
MV4-11 NFPkd4lHfW6ldHnvckBCe3OjeR?= Mn36NQKBmzIEoN88US=> MYm3NkBp M1zyfWROW09? M{\WUIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= MWOyOVY2QTd|MR?=
MUG-Chor  NIHvS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLMRYkyOC13IN88US=> NEXkcFEzPC92ODDo M{D5UmlEPTB;Nz6wOgKBkW6PIH\vdkA1QGh? MVqyOVY1ODF6NR?=
U-CH1  NXjWWnZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S5XFAuPSEQvF2= NIjLfHkzPC92ODDo NXXPO4llUUN3ME25MlA{6oDLbl2g[o9zKDR6aB?= MYiyOVY1ODF6NR?=
KATOIII NGn6R2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\kV|ExNzJyIH7N M2\qNFQ5KGh? NWGxbpNmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXiyOVY{PTB3NR?=
AGS  NH3UcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H4b|ExNzJyIH7N MU[0PEBp NF\1N5hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4LnTlI2PjN3MEW1
SACC-83 MUnGeY5kfGmxbjDBd5NigQ>? NIjnZpE2KG6P MVG0PEBp NVf2NmFX\GWlcnXhd4V{KG63Y3zlZZIh\XiycnXzd4lwdiCxZjDITWYuOc7z MWeyOVQ5PTZ|NR?=
INA-6 M4GwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHqTXM1OC13MECgcm0> NYK2T497PDhiaB?= M1G4OYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2Dq[VI2Ojl4OUe4
U-266 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfFSnRjOC13MECgcm0> MkDqOFghcA>? MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYCyOVI6Pjl5OB?=
MOLP-8 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTOdHoxNTVyMDDuUS=> NXPZW5hVPDhiaB?= NXfEdpZlcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3X5R|I2Ojl4OUe4
HG-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv0NE02ODBibl2= MX[0PEBp MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlrFNlUzQTZ7N{i=
NCI-H929 NYD4boYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK0W|JMOC13MECgcm0> MVi0PEBp NHPSZ5JqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3;UbVI2Ojl4OUe4
OPM-2 M1z5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfsW4pJOC13MECgcm0> MUC0PEBp NGSxfHVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWjKPYxiOjV{OU[5O|g>
L-363 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWwMVUxOCCwTR?= MYm0PEBp NGTlcIJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn35NlUzQTZ7N{i=
MOLP-2 NF\sfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\DNE02ODBibl2= MWe0PEBp M1OwdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnfZNlUzQTZ7N{i=
KMS-12-BM NHfVXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7xdYUxNTVyMDDuUS=> MUW0PEBp NYjUZmlxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2\KN|I2Ojl4OUe4
SK-MM-2 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\IXWd3OC13MECgcm0> NXXEUm1FPDhiaB?= MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVuyOVI6Pjl5OB?=
U-266 MXPBdI9xfG:|aYOgRZN{[Xl? M4n6UFAuPTBibl2= NWm4O|VvOjRiaB?= NIq3bYpqdmS3Y3XzJIFxd3C2b4Ppdy=> Ml3pNlUzQTZ7N{i=
INA-6  NGS1PFFCeG:ydH;zbZMhSXO|YYm= NXTUWolOOC13MDDuUS=> MmLSNlQhcA>? NEf4SY5qdmS3Y3XzJIFxd3C2b4Ppdy=> NYOyNZdtOjV{OU[5O|g>
MCF7 NH\WcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:z[GVuPzJiaB?= M2W3RWlEPTB;MUOgxtEhPiCwTR?= M4nQeVI2OjJyMkK1
MCF7-TamR6 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[3NkBp M4P1UWlEPTB;ODFCtUA3KG6P MnXXNlUzOjB{MkW=
MCF7-TamR7 NYW4SGtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XtSVczKGh? Mmf6TWM2OD16INMxJFMhdk1? NYHUZmp2OjV{MkCyNlU>
MCF7-TamR8 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[zcVczKGh? MoTMTWM2OD1zNTFCtUA3KG6P NFW2N20zPTJ{MEKyOS=>
MCF7-TamC3 NXTsOmszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPOO|IhcA>? MXXJR|UxRTZiwsGgN{BvVQ>? NEPGWnUzPTJ{MEKyOS=>
MCF7-TamC6 M4jmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGySGl[PzJiaB?= MoDJTWM2OD14INMxJFAvOSCwTR?= MnH2NlUzOjB{MkW=
MDA-MB-231 NUDoenVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOxT5c4OiCq MULJR|UxRTViwsGgNUBvVQ>? M13OZVI2OjJyMkK1
SK-BR-3 M1LKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnjWoM3PzJiaB?= NX;tWFE2UUN3ME23JOKyKDBwMzDuUS=> MojMNlUzOjB{MkW=
Eca109 MU\GeY5kfGmxbjDBd5NigQ>? MWWxMVUxKG6P NHXpUoU1QCCq M4\ndWROW09? M3GycZN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHu4TGEzPTF|OUO5OS=>
TE13 NWLCenFTTnWwY4Tpc44hSXO|YYm= Mn\QNU02OCCwTR?= MXi0PEBp MkDLSG1UVw>? NHjpZ|F{fXCycnXzd4V{KHO3co\peolvKGW6cILld5Nqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M33GdFI2OTN7M{m1
Eca109 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HrN|AuOTByIH7N NWTmUXd[OjRxNEigbC=> MWjEUXNQ MmLq[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVuyOVE{QTN7NR?=
TE13 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXuSoNmOC1zMECgcm0> M{exVFI1NzR6IHi= NET6UnVFVVOR NXHlVHJw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUmyOVE{QTN7NR?=
MT-3 MUDLbY5ie2ViQYPzZZk> M2\nbVczKGh? NXvrfVRlTE2VTx?= NF3OeIlKSzVyPUKuPFYhyrFiMD61OEBvVSCob4KgSHI1KGW6cILld5Nqd25? NULGOWY6OjR6Nk[1PFU>
MDA-MB-468 NX\YdYxLU2mwYYPlJGF{e2G7 NH6xRZc4OiCq MVzEUXNQ NEPBbFFKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? MlH3NlQ5PjZ3OEW=
SUM-159 MlqyT4lv[XOnIFHzd4F6 NF\CXnM4OiCq NGDo[HRFVVOR MV7JR|UxRTFwN{KgxtEhOC5|MzDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> M3WwT|I1QDZ4NUi1
MT-3 Mni4T4lv[XOnIFHzd4F6 MmThO|IhcA>? M{[2PGROW09? NF7mVpNKSzVyPUW0MlEyKMLzIESuN|Ihdk1iZn;yJGRTPSCneIDy[ZN{cW:w NV3vd4xIOjR6Nk[1PFU>
MDA-MB-468 NXLKOZlZU2mwYYPlJGF{e2G7 NHWwZVY4OiCq NYP3VoF5TE2VTx?= Moe0TWM2OD1yLkC3JOKyKDBwMEKgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v M4[1b|I1QDZ4NUi1
SUM-159 M3T5RmtqdmG|ZTDBd5NigQ>? NX3EPIRWPzJiaB?= MWHEUXNQ NYX5NnVXUUN3ME22PU41KMLzIESuNlMhdk1iZn;yJGRTPSCneIDy[ZN{cW:w MWiyOFg3PjV6NR?=
MT-3 + NAC M4jGd2tqdmG|ZTDBd5NigQ>? MXy3NkBp Mnn0SG1UVw>? MWPJR|UxRTV4LkKgxtEhOi5yNzDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> M13oNFI1QDZ4NUi1
MT-3 + SB203580 NWjjPW1pU2mwYYPlJGF{e2G7 MVW3NkBp MoXTSG1UVw>? M4rtZWlEPTB;M{iuOFEhyrFiNT6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? M1X5clI1QDZ4NUi1
DB MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v2UVExKG6P NUfVTFk5OjRiaB?= NUnkbG1wTE2VTx?= Mk\EbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NFvoWnMzPDR6NkW5OS=>
SU-DHL-8 NHO4[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\GUHAyOCCwTR?= MV6yOEBp MlfxSG1UVw>? NX3UZY1lcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NVjlbI5MOjR2OE[1PVU>
WSU-DLCL2 NGHsUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\pOoRvOTBibl2= M4XTO|I1KGh? NIXPdIxFVVOR NIqyUWJqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> NF\Jb3UzPDR6NkW5OS=>
ACC-2 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV63OXBTOC1zMECgcm0> MVeyOEBp MnXzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF7HUIwzPDN5MEm5OS=>
ACC-2 NVjSOZpVSXCxcITvd4l{KEG|c3H5 NFewXW4xNTJyIH7N MmDENlQhcA>? NIPXZ2hqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIO0ZVkzPDN5MEm5OS=>
ACC-2 MmXVSpVv[3Srb36gRZN{[Xl? NFzUPI8xNTJyIH7N NYq5NJAxOjRiaB?= M3Hmc4lv[3KnYYPld{B1cGViY3;ueoVze2mxbjDv[kBNSzOLIITvJGxEO0mL NXXtWHpqOjR|N{C5PVU>
BFTC905 NVjzT5dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn23NE0yODByIH7N NFy3VY41QCCqwrC= NWC2bpF5TE2VTx?= NELS[ZRKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NH\6XnUzPDJ7N{[0OC=>
T24 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDHNE0yODByIH7N MoHaOFghcMLi M1ewNWROW09? MoO5TWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEj6RnQzPDJ7N{[0OC=>
TSGH8301  NVfIVHlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSwMVExODBibl2= MYq0PEBpyqB? NXXmNYd3TE2VTx?= M2\1R2lEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUXTSZh3OjR{OUe2OFQ>
BFTC909 MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWwMVExODBibl2= M{DCZVQ5KGkEoB?= MmrpSG1UVw>? NGPLPGFKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkPpNlQzQTd4NES=
BFTC905 MlHURZBweHSxc3nzJGF{e2G7 MWOyNEBvVQ>? NEP6O3o1QCCq MV;EUXNQ MlzObY5lfWOnczDhdI9xfG:|aYO= MmrnNlQzQTd4NES=
BFTC905 MlSzSpVv[3Srb36gRZN{[Xl? NH7TSXIzOCCwTR?= MVS0PEBp NUPpNlJyTE2VTx?= Mljr[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEO0JvSVm= NF7RRYUzPDJ7N{[0OC=>
A2780p Mn32SpVv[3Srb36gRZN{[Xl? MkftNE0yODBibl2= NWnIbohIOjRiaB?= MlHoSG1UVw>? MnnsbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi M4i4R|I1OjZ{OEe1
A2780cis NU\YcINHTnWwY4Tpc44hSXO|YYm= NWLnNHVxOC1zMECgcm0> NUjmSJNWOjRiaB?= MV3EUXNQ NHq0doRqdmS3Y3XzJHN2en[rdnnuJIRwf26{ZXf1cIF1cW:wwrC= NWf0d3hUOjR{NkK4O|U>
A2780p M1\ZfGFxd3C2b4Ppd{BCe3OjeR?= M3TYSFUuOTByIH7N NX;vXFZDOjRxNEigbC=> NYfaV2YyTE2VTx?= MYHpcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy Mm\ZNlQzPjJ6N{W=
A2780cis MkT0RZBweHSxc3nzJGF{e2G7 NVPXdolXPS1zMECgcm0> M4XqPVI1NzR6IHi= NHvEbVJFVVOR NGr6UoZqdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NGnFU4UzPDJ4Mki3OS=>
SH-SY5Y M1rwcmFxd3C2b4Ppd{BCe3OjeR?= NIfnNXcyNzFyL{GwNEDDvU1? NVrxRY0zPzJiaB?= MVXEUXNQ MWrpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEDCbG0zPDJ3NEW2NC=>
HL-60 NGDhTppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG3NuKhcA>? MW\EUXNQ NXzRPY9XUUN3ME2wMlMhdk1? NHuzUXAzOzZzOEi2Ni=>
U937  NELxeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm3O|LDqGh? MUXEUXNQ MUjJR|UxRTBwODDuUS=> M3HSRVI{PjF6OE[y
HL-60  M3TXV2Z2dmO2aX;uJGF{e2G7 MXOxxsDPxE1? MoTuOk8yOi9{NDDo NWfzdVhiTE2VTx?= M4PpO4lvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu NX\n[|RkOjN4MUi4OlI>
U937  M4rt[2Z2dmO2aX;uJGF{e2G7 MXixxsDPxE1? M{i5SFYwOTJxMkSgbC=> MY\EUXNQ MUjpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDzeZJ3cX[rbh?= MWeyN|YyQDh4Mh?=
HL-60 NUO0SJM{SXCxcITvd4l{KEG|c3H5 MmTYNE4yNzFizszN NVy0TJB3QCCq MXTEUXNQ MmHUbY5lfWOnczDhdI9xfG:|aYO= MmDaNlM3OTh6NkK=
Sk-NEP-1  M13NW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TyeFEuOTByMECgcm0> MYWyOEBp NEPmcYtFVVOR NXLUT21pUUN3ME2xNFAhdk1? NF;xZnYzOzJ4N{[5PS=>
SK-NEP-1  MkPoRZBweHSxc3nzJGF{e2G7 NIXyPZM2OC9zMECgcm0> M3HvSFEzNzJ2IHi= M4TEeWROW09? MmTjbY5lfWOnczDhdI9xfG:|aYO= MmfkNlMzPjd4OUm=
TC-32 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\jNE4yNTFyMECgcm0> MlzqSWM2OD1|LkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVi1XWR3OjJ7NkG3OlM>
TC-71 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGwMlEuOTByMDDuUS=> M{PIRWVEPTB;NT63JI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2nrO|IzQTZzN{[z
SK-ES-1 NEDZUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj4NFQxNjFvMUCwNEBvVQ>? NUnoRnZkTUN3ME2yMlghdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkLhNlI6PjF5NkO=
RD-ES NXPxUFNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHuNE4yNTFyMECgcm0> M4m2NGVEPTB;Nj6yJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{XI[VIzQTZzN{[z
HEK293 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYewMlEuOTByMDDuUS=> MmrDSWM2OD1{Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFn3enQzOjl4MUe2Ny=>
M059J M4m2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUewMVUxKG6P MWW0PEBp M{\NNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkP5NlI4PzBzMUC=
M059K NWr2T25IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILXV4sxNTVyIH7N NIjZb3k1QCCq MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYLaVZRLOjJ5N{CxNVA>
M059J NF:4bZFCeG:ydH;zbZMhSXO|YYm= M3LGWFMxKG6P NGjVW|YzPCCq MWrpcoR2[2W|IHHwc5B1d3Orcx?= MYCyNlc4ODFzMB?=
M059K MWXBdI9xfG:|aYOgRZN{[Xl? NXvZ[XN1OzBibl2= NIfCSpAzPCCq NV:wdYRGcW6mdXPld{BieG:ydH;zbZM> NXLyPXBXOjJ5N{CxNVA>
PANC-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G2ZVAvODFvMUCwNEBvVQ>? M3[2TlQ5KGh? MYjJR|UxRTNwNkmgcm0> NGHkWIczOjd{M{i3NS=>
MIAPaCa-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr4NE4xOS1zMECwJI5O NXPlSXJFPDhiaB?= MkPrTWM2OD1{OT6zOkBvVQ>? MU[yNlczOzh5MR?=
BxPC-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXJNE4xOS1zMECwJI5O NHTE[I41QCCq NYHocZV1UUN3ME2zNE4zPiCwTR?= MVOyNlczOzh5MR?=
PANC-1 MlvISpVv[3Srb36gRZN{[Xl? NWLFbYZNOC1zMECwJI5O MVWyOEBp M4nNcYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> MnzkNlI4OjN6N{G=
MIAPaCa-2 NUTF[o1ITnWwY4Tpc44hSXO|YYm= MXuwMVExODBibl2= MlPGNlQhcA>? NWq3VmtucW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v M2f3SVIzPzJ|OEex
BxPC-3 MkC0SpVv[3Srb36gRZN{[Xl? M4LsO|AuOTByMDDuUS=> Mn;4NlQhcA>? M3zWcIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> NEj6cVgzOjd{M{i3NS=>
RPMI-7951 NGK3RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;XRXlIUTVyPUOuNkBvVQ>? NFHPR5YzOTd|N{WwNi=>
SK-MEL-5 NWKzO25uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jFU2dKPTB;ND6yJI5O M4K2OVIyPzN5NUCy
A375 NXvBRmlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC0XmFIUTVyPU[uN{BvVQ>? MUmyNVc{PzVyMh?=
SK-MEL-28 NH[0VGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7HTVUxRTdwNjDuUS=> MUCyNVc{PzVyMh?=
SK-MEL-2 NH;2RplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjHTVUxRTFzIH7N M3XP[FIyPzN5NUCy
DB MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXS0POKhcA>? NXXrVFMzT0l3ME2zMlUhdk1? M4nvNlIyOjN5NUC4
Pfeiffer MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYe0POKhcA>? MUnHTVUxRTNwOTDuUS=> NXrXV|VHOjF{M{e1NFg>
SU-DHL-5 M4DZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z5NFQ5yqCq NU\2fXZsT0l3ME2wMlI{KG6P NVrjfXZWOjF{M{e1NFg>
SU-DHL-8 NETiNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzQOFjDqGh? NWnL[XJUT0l3ME2xMlQhdk1? MXeyNVI{PzVyOB?=
WSU-DLCL-2 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTQOFjDqGh? M4DOUGdKPTB;MT60JI5O NGfuVXEzOTJ|N{WwPC=>

... Click to View More Cell Line Experimental Data

In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

+ Expand
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Formulation: Dissolved and diluted in saline immediately before administration
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01100931 Completed NSCLC|Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 2010 Phase 1|Phase 2
NCT01100931 Completed NSCLC|Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 2010 Phase 1|Phase 2
NCT01038804 Completed Breast Cancer Astellas Pharma Inc December 2009 Phase 2
NCT01038804 Completed Breast Cancer Astellas Pharma Inc December 2009 Phase 2
NCT01023386 Completed Cancer Astellas Pharma Inc November 2009 Phase 1
NCT01009775 Completed Melanoma Astellas Pharma Inc November 2009 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products0

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID